AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $37.33M rose 57329.2% year over year, ahead of the +42373.9% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -88.3% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +57329.2% holds above the trailing-twelve-month pace of +42373.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 113K USD
- Year-over-year change
- -69.6%
- 4-year CAGR
- -80.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 113K | -69.6% |
| FY2024 | 2024-12-31 | 372K | -99.6% |
| FY2023 | 2023-12-31 | 84.99M | +20.8% |
| FY2022 | 2022-12-31 | 70.36M | -10.4% |
| FY2021 | 2021-12-31 | 78.54M | — |
Financing Cash Flow vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's LTM Mar 2026 financing cash flow of $37.38M is the 3rd largest of the 6 companies compared; the peer median is $5.67M.
- Its year-over-year change of +42373.9% is the highest of 6, against a peer median of +234.8%.
- Over three fiscal years its annual growth of -88.3% compares with a peer median of +255.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $350.85M | +33009.9% | +443.0% | — | |
| LTM Jun 2026 | $103.05M | +1054.1% | +255.1% | 103048.0% | |
| LTM Mar 2026 | $37.38M | +42373.9% | -88.3% | — | |
| LTM Mar 2026 | $5.67M | +234.8% | — | 10.6% | |
| LTM Mar 2026 | $5.38M | -84.3% | — | 14.5% | |
| LTM Mar 2026 | $141K | -99.8% | +3.8% | — | |
| Peer median (excluding ANTX) | $5.67M | +234.8% | +255.1% | 14.5% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 974K | 4.39M | 8.41M | 8.34M | 6.25M |
| Change in Working Capital | 32K | 3.72M | 5.83M | (3M) | 164K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 417K | 2.5M | 553K | 641K | (296K) |
| Other Working Capital | (385K) | 1.22M | 5.28M | (3.64M) | 460K |
| Other Non-Cash Items | 53K | (615K) | (2.8M) | (3.28M) | (1.07M) |
| Operating Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.27M) | (93.84M) | (132.18M) | (46.75M) | (46.19M) |
| Sales of Investments | 27.25M | 72.07M | 88.9M | 101.34M | 74.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.02M) | (21.77M) | (43.28M) | 54.59M | 28.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 70.37M | 84.53M | 372K | 113K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.2M) | (11K) | 465K | 0 | 0 |
| Financing Cash Flow | 78.54M | 70.36M | 84.99M | 372K | 113K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.03M | 15.12M | (11.57M) | 5.7M | (1.41M) |
| Free Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.